About Survodutide
Survodutide is studied as a dual GLP-1 receptor and glucagon receptor agonist in metabolic research. Supplied as a lyophilized powder for laboratory investigations into incretin/glucagon receptor pharmacology and energy-metabolism pathway markers in controlled experimental models. Each batch is verified for identity and purity using HPLC and mass spectrometry. Supplied as: Lyophilized powder Purity: 99%+ (HPLC verified) Storage: Store desiccated at ?20�C for long-term. Short-term room temperature exposure (around 1 month) during shipping/handling is generally acceptable if kept sealed, dry, and protected from heat/light. Designation: FOR RESEARCH USE ONLY. Not intended for human or animal consumption.
Latest Research
Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR/GLP-1R agonist survodutide in mice.
Recent research on Survodutide: Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR/GLP-1R agonist survodutide in mice.
Read Full Study on PubMedSurvodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation.
Recent research on Survodutide: Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation.
Read Full Study on PubMedAdditional Studies
Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.
Recent research on Survodutide: Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.
Read on PubMedOperationalising disease modification in obesity trials: A blueprint based on the SYNCHRONIZE-1 survodutide study.
Recent research on Survodutide: Operationalising disease modification in obesity trials: A blueprint based on the SYNCHRONIZE-1 survodutide study.
Read on PubMedBaseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.
Recent research on Survodutide: Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.
Read on PubMedOptimization of patient and site engagement in the SYNCHRONIZE™ phase 3 clinical trial program for survodutide in obesity through clinical trial simulation.
Recent research on Survodutide: Optimization of patient and site engagement in the SYNCHRONIZE™ phase 3 clinical trial program for survodutide in obesity through clinical trial simulation.
Read on PubMedComparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta-Analysis of Clinical Trials.
Recent research on Survodutide: Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta-Analysis of Clinical Trials.
Read on PubMedIUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes.
Recent research on Survodutide: IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes.
Read on PubMedRelated Research
Purchase Survodutide from Verified Peptides
High-purity research peptides with full analytical verification
- 99% Purity (HPLC Verified)
- Full Certificate of Analysis
- Same Day Dispatch
- Free UK Shipping Over £75
Research Disclaimer
The research articles and studies referenced on this page are for informational purposes only. All products are sold for research use only and are not intended for human or animal consumption. The information provided does not constitute medical advice, diagnosis, or treatment. Always consult with qualified healthcare professionals before making any decisions related to health or medical treatment.